A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma

Figures & data

Table 1 Clinical Response Rate (RECIST Criteria)¹⁵

Clinical Response	Frequency	Percent
Complete Response	16	26.6%
Partial Response	30	50%
No Response	8	13.3%
Progressive Disease	6	10%
Total	60	100%

Table 2 Pre-NACT T-Stage vs Post-NACT T-Stage

		Post Chemotherapy Tumor Stage					Total
		T0	T1	T2	T3	T4
Pre-Chemotherapy Tumor Stage	T2	2	0	2	0	0	4
		3.3%	0.0%	3.3%	0.0%	0.0%	6.6%
	T3	12	5	3	4	0	24
		20%	8.3%	5%	6.6%	0%	40.0%
	T4	2	10	8	4	8	32
		3.3%	16.6%	13.3%	6.6%	13.3%	53.3%
Total		16	15	13	8	8	60
		26.7%	25%	21.6%	13.3%	13.3%	100.0%

Note:P-value<0.05.

Table 3 Pre-NACT Nodal Stage vs Post-NACT Nodal Stage

		Post-Chemotherapy Nodal Stage			Total
		N0	N1	N2
Pre-Chemotherapy Nodal Stage	N0	8	0	0	8
		13.3%	0.0%	0.0%	13.3%
	N1	26	14	0	40
		43.3%	23.3%	0.0%	66.7%
	N2	6	2	4	12
		10.0%	3.3%	6.7%	20.0%
Total		40	16	4	60
		66.7%	26.7%	6.7%	100.0%

Note:P-value<0.05.

Table 4 Post-NACT Response Rate Compared with Age, Menopausal State, ER, PR Her2neu, Tumor Grade, and Tumor Histology (Percentage within Group)

		Complete Response	Partial Response	Stable	Progressive	Total
Age	<50	1 (2.7%)	23 (63.8%)	6 (16.6%)	6 (16.6%)	36
(P<0.05)	51 and above	15 (62.5%)	7 (29%)	1 (4%)	1 (4%)	24
Menopausal state
	Pre- menopausal	4 (16%)	10 (4%)	5 (2%)	6 (24%)	25
(P<0.05)	Post- menopausal	12 (34.2%)	20 (57%)	3 (8.5%)	0 (0%)	35
ER status
(P<0.05)	Positive	14 (38.8%)	20 (55.5%)	2 (5.5%)	0 (0%)	36
	Negative	2 (8.3%)	10 (41.6%)	6 (25%)	6 (25%)	24
PR status
(P=0.385)	Positive	10 (32.2%)	16 (51.6%)	3 (9.6%)	2 (6.4%)	31
	Negative	6 (20.6%)	14 (48.2%)	5 (17.2%)	4 (13.7%)	29
Her2 -neu
(P=0.309)	Positive	10 (31.2%)	17 (53%)	3 (9.3%)	2 (6.2%)	32
	Negative	6 (21.4%)	13 (46.4%)	5 (17.8%)	4 (14.2%)	28
Grade
(P=0.143)	1 and 2	6 (28.5%)	11 (52%)	3 (14.2%)	1 (4.7%)	21
	3	10 (25.6%)	19 48.7%)	5 (12.8%)	5 (12.8%)	39
Histology
(P<0.05)	Invasive ductal CA	14 (32.5%)	22 (51%)	5 (11.5%)	2 (4%)	43
	Invasive lobular CA	0 (0%)	5 (55.5%)	1 (11%)	3 (33.3%)	9
	Others and mixed	2 (25%)	3 (37.5%)	2 (25%)	1 (12.5%)	8

Table 5 Clinical and Pathological Response in Molecular Sub-types

	Luminal A (19) 31.6%	Luminal B (22) 36.6%	TNBC (9)15%	HER2 (10)16%	P-value
Complete response (16)	4 (21.1%)	10 (45.5%)	2 (22.2%)	0	0.046 (<0.05)
Partial response (30)	13 (68.4%)	7 (31.6%)	5 (55.6%)	5 (50%)	0.133 (>0.05)
Total response	17 (90%)	17 (77%)	7 (78%)	5 (50%)	0.126 (>0.05)
Static disease (8)	2 (10.5%)	3 (13.6%)	0	3 (30%)	0.270 (>0.05)
Progressive disease (6)	0	2 (9.1%)	2 (22.2%)	2 (20%)	0.192 (>0.05)
Pathological response (8)	3 (15.7%)	3 (13.6%)	2 (22.2%)	0	0.324 (>0.05)

EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247

 Google Scholar